Clinical Trial Update: An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives [Phase 3]

View source ↗

Summary

Expanded access protocol for esketamine in treatment-resistant depression completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Esketamine (esketamine)

Snippet

Sponsor: Janssen-Cilag, S.A. | Conditions: Depression | Phase 3 | Status: COMPLETED